A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75

Leukemia

Volumn 10, Issue 3, 1996, Pages 389-395

  Reiffers, J ^a   Huguet, F ^b   Stoppa, A M ^c   Molina, L ^d   Marit, G ^a   Attal, M ^b   Gastaut, J A ^c   Michallet, M ^d   Lepeu, G ^e   Broustet, A ^a   Pris, J ^b   Maraninchi, D ^c   Hollard, D ^d   Faberes C ^a   Mercier, M ^f   Hurteloup, P ^g   Danel, P ^g   Tellier, Z ^g   Berthaud, P ^g  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b CHU PURPAN   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e CH Avignon   (France)

^f UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^g Pharmacia SA   (France)

Author keywords

Acute myeloid leukemia; Anthracycline; Idarubicin; Induction chemotherapy

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 9244253691     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Champlin RE, Gajewski, JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989; 16: 51-56.
2. Gale RP, Foon kA, Cline MJ, Zighelboim J. Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 1981; 94: 753-757.
3. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989; 16: 66-75.
4. Kempton J, Rees H. Chemotherapy of the leukemias. In: Freireich EJ (ed). New Approaches to the Treatment of Leukemia. Springer-Verlag: Berlin, Heidelberg, 1990, pp 5-77.
5. Foon KA, Gale RP. Therapy of acute myelogenous leukemia. Blood Rev 1992; 6: 15-25.
6. Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharmacol 1992; 11; 152-167.
7. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19: 670-686.
8. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 1977; 37: 4523-4528.
9. Schwartz HS, Kanter PM. DNA damage by anthracycline drugs in human leukemia. Cancer Lett 1981; 13: 309-313.
10. Zunino F, Gambetta R, Di Marco A, Luoni G, Zaccara A. Effects of the stereochemical configuration on the interaction of some daunomycin derivatives with DNA. Biochem Biophys Res Commun 1976; 69: 744-748.
11. Plumbridge TW, Brown JR. Studies on the mode of interaction of 4′-epi-adriamycm and 4-demethoxydaunorubicin with DNA. Biochem Pharmacol 1978; 27: 1881-1882.
12. Rose KM. DNA topoisomerases as targets for chemotherapy. FASEB J 1988; 2: 2474-2478.
13. Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 1977; 13: 901-910.
14. Cairo MS, Toy C, Sender L, Van de Ven C. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin. J Leuk Biol 1990; 47: 224-233.
15. Herman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
16. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Wiltiams L, Baratz R, Young CW. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983; 43: 6096-6101.
17. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 1985; 45: 1408-1412.
18. Reid JM, Pendergrass TW, Krailo MD, Hammond CD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 1990; 50: 6525-6528.
19. Speth PAJ, Van de Loo FAJ, Linssen PCM, Wessels HMC, Haanen C. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 1986; 40: 643-649.
20. Boiron JM, Belloc F, Montastruc M, Cony-Makhoul P, Dumain P, Marit G, Mahon FX, Puntous M, Lopez F, Lacombe F, Reiffers J. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia. Leuk Res 1994; 18: 313-318.
21. Friche E, Buhl Jensen P, Roed H, Skovsgaard T, Nissen NI. In vitro circumvention of anthracycline resistance in Ehrlich ascites tumour by anthracycline analogues. Biochem Pharm 1990; 39: 1721-1726.
22. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
23. Hill BT, Dennis LY, Li XT, Whelan RDH. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 1985; 14: 194-201.
24. Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, Hancock C, Williams L, Stevens YW, Clarkson BD, Young C. 4-demethoxydaunorubicin (idarubicin) in combination with 1-β-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Res 1989; 49: 477-481.
25. Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, Clarkson BD. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 1989; 16 (Suppl. 2): 30-34.
26. Berman E, Weiss M, Kempin S, Gee T, Bertino J, Clarkson B. Intensive therapy for adult acute lymphoblastic leukemia. Semin Hematol 1991; 28: 72-75.
27. Carella AM, Pungolino E, Piatti G, Gaozza E, Nati S, Spriano M, Giordano D, D'Amico T, Damasio E. Idarubicin in combination with intermediate dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur J Haematol 1989; 43: 309-313.
28. Harousseau JL, Huguet F, Reiffers J, Colombat P, Kohser P, Le Prise PY, Souteyrand P, Hurteloup P. Oral idarubicin and low-dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma 1991; 15: 145-149.
29. Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, Le Prise PY, Monconduit M, Jaubert J, Carcassonne Y. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat Rep 1987; 71: 991-992.
30. Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N, for the French Study Group of Idarubicin in Leukemia. Treatment of relapse acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 1989; 7: 45-49.
31. Lambertenghi-Deliliers G, Maiolo AT, Annaloro C, Cortelezzi A, Pogliani E, Ganzina F, Polli EE. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. Eur J Cancer Clin Oncol 1987; 23: 1041-1045.
32. Mandelli F, Testi AM, Aloe Spiriti MA, Giona F, Meloni G, Moleti ML, Amadori S, Pacciarini MA. Evaluation of polychemotherapeutic regimen including idarubicin (4-demethoxydaunorubicin) in relapsed acute lymphocytic leukemia. Haematologica 1986; 71: 34-38.
33. Petti MC, Mandelli F. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA. Semin Oncol 1989; 16 (Suppl. 2): 10-15.
34. Pui CH, de Graff SSN, Dow LD, Rodman JH, Evans WE, Alpert BS, Murphy SB. Phase 1 clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1988; 48; 5348-5352.
35. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreef M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
36. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group experience. J Clin Oncol 1992; 10: 1103-1111.
37. Wiernik PH, Banks PLC, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
38. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, Falconi E, Geraci E, Ladogana S, Latagliata R, Malleo C, Nobile F, Petti N, Rotoli B, Specchia G, Tabilio A, Resegotti L. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. Eur J Cancer 1991; 27: 750-755.
39. Reiffers J, Rigal-Huguet F, Stoppa AM, Michallet M, Marit G, Attal M, Gastaut JA, Corront B, Lepeu G, Routy M, Cony-Makhoul P, Pris J, Hollard D, Maraninchi D, Mercier M, Hurteloup P, for the BGMT Group. Prospective study comparing idarubicin and daunorubicin in elderly patients with acute myeloid leukemia. Haematol Blood Trans 1992; 34: 628-631.
40. Preisler HD, Reese PA, Marinello MJ, Pothier L. Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure. Br J Haematol 1983; 53: 459-466.
41. Reiffers J, Gaspard MH, Maraninchi D, Michallet M, Marit G, Stoppa AM, Corront B, David B, Gastaut JA, Sotto JJ, Broustet A, Carcassonne Y, Hollard D. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: 57-63.
42. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F. Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia: a randomized controlled study. New Engl J Med 1990; 323: 871-877.
43. Büchner T, Hiddemann W, Koenigsmann M, Zuhlsdorf M, Wörmann B, Boeckmann A, Aguion Freire E, Innig G, Maschmeyer G, Ludwig WD, Sauerland MC, Hemecke A, Schulz G. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190-1197.